Table 2.

Initial treatment, salvage therapy and outcome of 6 R/R ALAL-NOS patients

No.	Previous treatment	Reinduction treatment	VEN dose, (mg)	VEN days	Response to VEN combination	HSCT	Outcome	OS(m)
1	Chemotherapy and HSCT	VEN + AZA	400 mg	28d	CR	N	Dead	36
2	VDCP NR; DAC + HACVP NR	VEN + AAVP	400 mg	14d	CR	Y	CR	15
3	VDCP NR; DAC + HACVP NR	VEN + AAVP PR; DAC + VEN + AAVP	400 mg	21d	CR	Y	Dead	9
4	DAC + AAVP NR	VEN + HOAP	200 mg (with voriconazole)	14d	CRi	Y	CR	8
5	VDCP + AA NR	VEN + CA	400 mg	14d	CR	Y	CR	7
6	AACVP NR	VEN + HOAP	400 mg	14d	CR	Y	CR	5

VEN, venetoclax; DAC, decitabine; AZA, azacitidine; VCR, vincristine; DNR, daunorubincin; CTX, cyclophosphamide; Pred, prednisone; HHT, homoharringtonine; Ara-c, cytarabine; Acla, aclarubicin. VDCP:VCR + DNR + CTX + Pred; HACVP, HHT + Ara-c + CTX + VCR + Pred; AAVP, Ac,a + Ara-c + VCR + Pred; AA, Acla + Ara-c; CA cladribine + LDAC; AACVP, Acla + Ara-c + CTX + VCR + Pred; HOAP: HHT + Ara-c + VCR + Pred; HSCT, hematopoietic stem cell transplantation